Emerging Trends in cervical cancer Treatment: Transitioning from traditional to innovative delivery strategies
Cervical cancer (CC) remains the second most common cause of cancer-related deaths among women in the United States, following breast cancer. As per American Cancer Society reports, with approximately 4,320 deaths expected annually, it continues to pose a significant threat to global public health. The highest prevalence of CC has been reported in low to middle-income nations in Asia, Africa, and Latin America, where screening and treatment are scarce. Although surgery, radiation therapy, and chemotherapy have long been the cornerstones of CC care, their drawbacks, such as exorbitant expenses, restricted availability, and serious side effects, including neuropathy and infertility, highlight the need for creative alternatives. Current research demonstrates the effectiveness of cutting-edge treatments; for example, pembrolizumab (FDA approval, 2021) immunotherapy has been shown to improve progression-free survival in metastatic CC by 30%. In preclinical models, drug delivery systems based on nanotechnology, such as cisplatin-loaded nanoparticles, have shown a 40% increase in tumor drug concentration with decreased systemic toxicity. By addressing the limitations of existing treatments and concentrating on the pathophysiology of the illness, particularly HPV-driven oncogenesis, this study explores the shift from traditional to advanced CC therapy. It looks at diagnostic innovations such as early detection using MRI and ultrasound, as well as molecular diagnostics with computer-aided methods that have a 25% higher sensitivity in detecting precancerous lesions. The review also discusses therapeutic innovations, ranging from conventional methods like surgery and chemotherapy to newer approaches like photodynamic therapy, which has been shown to reduce tumors by 60% in early-stage CC trials, nanomedicine, targeted therapies (like bevacizumab), localized drug delivery via vaginal gels, nanofibers, intravaginal rings, immunotherapy, and gene therapy. It provides a thorough understanding of the changing treatment environment by analysing ongoing clinical studies and patient patterns.
